Hot off the Forge
-
FUEL™ platform can achieve a 2-6x increase in productivity compared to industry standard, and includes pEMBR 2.0™ Ad helper and…
-
John Maslowski, Chief Commercial Officer, to succeed Dr. Timothy Miller as President and CEO. “It’s an exciting time at Forge.”
-
“Forge has proven to be a trusted partner to gene therapy innovators, advancing many critical programs for rare diseases” Sharon…
-
“As we continue to advance how genetic medicines are manufactured, we are thrilled to present data showcasing our novel molecular…
-
Designation grants Forge’s FBX-101 therapy access to enter the Innovative Licensing and Access Pathway (ILAP).
-
Five patients have received FBX-101, all of whom were identified by newborn screening.
-
Research findings indicate a path to the development of potentially safer adeno-associated virus (AAV) gene therapies.
-
Acquisition positions Forge for accelerated long-term growth supporting gene and cell therapy clients worldwide.
-
Forge joins the CIRM Industry Resource Partner Program and will enable accelerated research and cGMP AAV manufacturing to CIRM-funded programs.
-
Forge will be delivering presentations, participating in fireside chats, and taking one-on-one meetings at four September investor conferences.
-
“Forge has proven to be a trusted partner to many gene therapy developers.”
-
Christopher Shilling to represent Forge on the BGTC’s Steering Committee, which will work towards speeding the process of gene therapy…
ESCGT 2026 Annual Congress
Bringing together experts, researchers, and professionals in gene and cell therapy.